Filing Details
- Accession Number:
- 0001447028-24-000025
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-02-05 19:54:09
- Reporting Period:
- 2024-02-01
- Accepted Time:
- 2024-02-05 19:54:09
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1447028 | Arbutus Biopharma Corp | ABUS | Pharmaceutical Preparations (2834) | 980597776 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1635326 | J. Michael Mcelhaugh | C/O Arbutus Biopharma Corporation 701 Veterans Circle Warminster PA 18974 | Interim President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Shares | Acquisiton | 2024-02-01 | 123,800 | $0.00 | 1,514,957 | No | 4 | A | Direct | |
Common Shares | Disposition | 2024-02-02 | 10,164 | $2.31 | 1,504,793 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Shares | Stock Option (Right to Buy) | Acquisiton | 2024-02-01 | 495,100 | $0.00 | 495,100 | $2.40 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
495,100 | 2034-02-01 | No | 4 | A | Direct |
Footnotes
- Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
- Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on March 3, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of a previous grant of restricted stock units.
- Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
- This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.